Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IA Trial of Combined Murine IgG Monoclonal Anti-Transferrin Receptor Antibodies E2.3 and A27.15 in Cancer Patients

NCT00003082 is registered in ClinicalTrials.gov with University of Arizona as lead sponsor.

NCT NCT00003082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IA Trial of Combined Murine IgG Monoclonal Anti-Transferrin Receptor Antibodies E2.3 and A27.15 in Cancer Patients
Lead sponsor
University of Arizona
Phase
Phase 1
Overall status
Completed
Start date
December 31, 1997
Completion date
February 28, 2001
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloproliferative disorders, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, precancerous/nonmalignant condition, unspecified adult solid tumor, protocol specific